MBX Biosciences, Inc. (MBX)

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company developing peptide therapies for endocrine and metabolic disorders. Its Precision Endocrine Peptide platform is designed to create long-acting prodrugs of therapeutic peptides that release the active drug steadily in the body, allowing less frequent dosing and more consistent drug levels.

The company's lead candidate, canvuparatide, is a once-weekly parathyroid hormone prodrug being developed for chronic hypoparathyroidism. Its pipeline also includes a GLP-2 prodrug for post-bariatric hypoglycemia and long-acting peptide candidates for obesity.

MBX Biosciences is headquartered in Carmel, Indiana, and completed its initial public offering on the Nasdaq in 2024.